CorMedix, Inc. announced via press release on June 8, 2026, that the U.S. Court of Appeals for the Federal Circuit affirmed a district court judgment that Nexus Pharmaceuticals Inc.'s generic minocycline product infringed two of the Company's patents. The decision rejected Nexus's invalidity challenge against the patent infringement.
